Beactica Announces Fragment-Based Drug Discovery Research Collaboration With GE Healthcare and Uppsala University



    UPPSALA, Sweden, Jan. 13 /CNW/ - Beactica AB, the Swedish fragment-based
drug discovery company, today announced a new research collaboration agreement
with GE Healthcare (Chalfont St. Giles, UK), the world leading provider of
molecular interaction analysis tools, and Uppsala University (Sweden). The
collaboration combines Beactica's unique approach to fragment-based drug
discovery and GE Healthcare's Biacore(TM) technology with enzymology expertise
from Uppsala University.
    (Logo: http://www.newscom.com/cgi-bin/prnh/20090113/333930)
    Under the terms of the agreement, the consortium will collaborate to
develop the next generation of Biacore(TM) surface plasmon resonance
instruments and applications for fragment-based drug discovery. The project
also aims to identify novel high-quality leads against a clinically important,
undisclosed protein target from Beactica's discovery pipeline. Financial terms
of the agreement were not disclosed.
    "We look forward to deepening our relationship with GE Healthcare and
Uppsala University," said Beactica's CEO, Dr Per Kallblad. "The Biacore
technology is a core component of our kinetics-integrated lead discovery
platform. Being an active part in the development of next-generation
applications from GE Healthcare will enable us to stay at the forefront of our
field."

    About Beactica

    Beactica AB is a specialist drug discovery company, utilising its
proprietary methodologies to evaluate the biophysical interaction of molecules
in order to generate novel therapeutics. The company was spun out of Uppsala
University in August 2006. As well as building collaborations with external
companies, Beactica is progressing its own drug discovery programmes of small
molecule therapeutics. For more information about Beactica, please visit
http://www.beactica.com.

    Photo: http://www.newscom.com/cgi-bin/prnh/20090113/333930





For further information:

For further information: Dr Per Kallblad, CEO Beactica, +46(0)18-560880

Organization Profile

BEACTICA AB

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890